by Tony Akiwumi | Nov 8, 2025 | Pharma / Market Access
Market access has a branding problem. It’s often seen as the administrative stage between regulatory approval and commercial launch. But in truth, access-first thinking can make or break a product’s commercial success — and save billions in missed revenue. Most failed...
by Tony Akiwumi | Nov 8, 2025 | Pharma / Market Access
Pharma loves strategy. There are workshops, frameworks, and slides with more arrows than a medieval battlefield. But when it comes to early adoption, strategy alone is never enough. What really matters is communication. You can have the most sophisticated launch plan...
by Tony Akiwumi | Nov 8, 2025 | Pharma / Market Access
When we talk about patient access in Europe or the US, the focus is usually on reimbursement, HTAs, or price negotiations. But in many emerging markets, access looks entirely different. It’s not about policy debates — it’s about getting medicines to patients in the...
by Tony Akiwumi | Nov 8, 2025 | Pharma / Market Access
Pharma’s digital revolution promised transformation. Apps for patients. Dashboards for payers. AI tools to predict outcomes. Yet for every digital success, dozens quietly fade into obscurity. The problem rarely lies in the technology itself. It lies in human adoption....
by Tony Akiwumi | Nov 8, 2025 | Pharma / Market Access
If you’ve ever sat in a cross-functional meeting, you’ll recognise the signs. Commercial wants bold claims. Regulatory insists on restraint. Medical clings to accuracy like a life raft. Market Access quietly sighs, repeating payer feedback that no one seems to want to...
by Tony Akiwumi | Nov 8, 2025 | Pharma / Market Access
Randomised controlled trials are tidy, logical, and beloved by regulators. But once a product leaves the pristine world of trial centres and meets real patients, the picture changes. Real-world evidence (RWE) decides whether a therapy’s promise holds up under pressure...
